Vanguard Personalized Indexing Management LLC Acquires 4,453 Shares of Sight Sciences, Inc. $SGHT

Vanguard Personalized Indexing Management LLC grew its holdings in Sight Sciences, Inc. (NASDAQ:SGHT) by 38.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,888 shares of the company’s stock after acquiring an additional 4,453 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Sight Sciences were worth $66,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. WealthTrust Asset Management LLC boosted its holdings in Sight Sciences by 230.2% in the 1st quarter. WealthTrust Asset Management LLC now owns 43,590 shares of the company’s stock valued at $105,000 after purchasing an additional 30,390 shares during the period. Nuveen LLC bought a new stake in shares of Sight Sciences in the first quarter valued at about $154,000. Long Focus Capital Management LLC lifted its stake in shares of Sight Sciences by 39.7% in the first quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company’s stock valued at $7,504,000 after buying an additional 887,876 shares during the period. AQR Capital Management LLC acquired a new stake in Sight Sciences during the first quarter worth about $128,000. Finally, Acadian Asset Management LLC increased its stake in Sight Sciences by 127.7% during the first quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock valued at $1,033,000 after acquiring an additional 242,559 shares during the period. Institutional investors own 55.51% of the company’s stock.

Insider Activity

In other Sight Sciences news, insider Jeremy B. Hayden sold 9,731 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $3.27, for a total value of $31,820.37. Following the completion of the sale, the insider directly owned 256,590 shares in the company, valued at $839,049.30. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Badawi sold 24,441 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total value of $81,632.94. Following the sale, the chief executive officer directly owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. The trade was a 0.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,796 shares of company stock valued at $135,173 over the last 90 days. Corporate insiders own 30.90% of the company’s stock.

Sight Sciences Stock Performance

Shares of Sight Sciences stock opened at $5.28 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 10.01 and a quick ratio of 9.49. The firm has a 50 day simple moving average of $3.82 and a 200 day simple moving average of $3.64. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $5.48. The firm has a market cap of $276.50 million, a P/E ratio of -5.50 and a beta of 2.41.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative net margin of 64.23% and a negative return on equity of 59.38%. The business had revenue of $12.54 million during the quarter. Sell-side analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SGHT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sight Sciences in a research note on Saturday. Lake Street Capital lifted their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Thursday, August 28th. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Finally, Morgan Stanley upped their price objective on Sight Sciences from $3.00 to $4.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.67.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.